Genetic screening of liver cancer: State of the art

doi:10.4254/wjh.v16.i5.716

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1733)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

HTML

1001

Figures (1-2)

190

Tables (1-2)

153

Sum=1416

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

190

Sum=261

May 27, 2024 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. May 27, 2024; 16(5): 716-730
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.716

Open in New Tab Full Size Figure Download Figure

Figure 1 Etiological and genetic factors in the oncogenesis of primary liver cancer. DM: Diabetes mellitus; miR: MicroRNAs; TP53: Tumor protein P53; CTNNB1: Catenin beta-1; AARID1A: AT-rich interaction domain 1; HBV: Hepatitis B virus; HCV: Hepatitis C virus; SNPs: Single nucleotide polymorphisms.

Open in New Tab Full Size Figure Download Figure

Figure 2 Barcelona clinic liver cancer staging system. The method of treatment is determined according to the stage. the method of treatment is determined according to the stage. RFA: Radiofrequency ablation; TACE: Transarterial chemoembolization; HIFU: High-intensity focused ultrasound; MWA: Microwave ablation; ECOG: Eastern cooperative oncology group; HDR: High dose rate; PS: Performance status; SBRT: Stereotactic body radiotherapy; SIRT: Selective internal radiotherapy; AFP: Alpha fetoprotein.

Citation: Peruhova M, Banova-Chakarova S, Miteva DG, Velikova T. Genetic screening of liver cancer: State of the art. World J Hepatol 2024; 16(5): 716-730
URL: https://www.wjgnet.com/1948-5182/full/v16/i5/716.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i5.716